Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

http://www.businessweek.com/ap/2012-12-24/j-dot-c-dot-penney-rite-aid-rim-are-market-movers

AP News

J.C. Penney, Rite Aid, RIM are market movers


NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and Nasdaq Stock Market:

NYSE

J.C. Penney Company Inc., up 28 cents at $19.87

Analysts at Oppenheimer reiterated a "Buy" rating on the retailer, saying that traffic in stores was strong the weekend before Christmas.

Rite Aid Corp., up 8 cents at $1.31

The drugstore chain's stock continued to rise after the company said last week that it filled more prescriptions in its third quarter.

Sturm, Ruger & Co. Inc., up 74 cents at $44.33

The gun maker's shares rose again on evidence that firearm sales are rising on fears of tighter gun laws after the school shooting at Newtown, Conn.

Acorn International Inc., up 47 cents at $2.68

The Chinese media company said that it will buy nearly 8 million of its shares, or 2.6 million of its American depositary shares.

Nike Inc., up 50 cents at $105.60

Shares of the athletic gear maker rose again after it posted second-quarter net income on Friday that beat analysts' expectations.

Nasdaq

Research In Motion Ltd., down 30 cents at $10.61

Shares of the BlackBerry maker fell again, after it said last week that it lost subscribers for the first time in the latest quarter.

Aegerion Pharmaceuticals Inc., down 46 cents at $25.25

The drug developer said that federal regulators approved its cholesterol drug, but it will carry a warning for liver damage.

Raptor Pharmaceuticals Corp., down 35 cents at $5.39

The drugmaker said that the Food and Drug Administration needs more time to review its potential nephropathic cystinosis treatment.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus